Live Feeds
● TRACKER Updated 23d ago · 11 sources tracked

How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink

A personalized mRNA cancer vaccine developed by Moderna and Merck has shown promise in late-stage trials by preventing melanoma from returning. The announcement triggered a massive surge in Moderna's stock, with reports of a single-day jump between 90% and 177%. This development suggests that vaccinating against cancer is now a viable possibility. While the results have sparked a broad biotech rally, some analysts caution that market enthusiasm may be outpacing the actual financial mathematics of the breakthrough.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (13)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ A late-stage trial of a Moderna and Merck cancer vaccine showed promise in preventing melanoma from returning.
  • ✓ Moderna stock experienced a significant surge following the trial results.
🛡️ Source Corroboration: 11 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Moderna and Merck released late-stage trial results showing their mRNA vaccine prevents melanoma recurrence.

Live updates

  1. Moderna and Merck mRNA Vaccine Prevents Melanoma Recurrence

    A personalized mRNA cancer vaccine developed by Moderna and Merck has shown promise in late-stage trials by preventing melanoma from returning. The announcement triggered a massive surge in Moderna's stock, with reports of a single-day jump between 90% and 177%. This development suggests that vaccinating against cancer is now a viable possibility. While the results have sparked a broad biotech rally, some analysts caution that market enthusiasm may be outpacing the actual financial mathematics of the breakthrough.

    Why it matters

    Moderna is pivoting its mRNA technology from Covid-19 applications to oncology. This shift follows a period of financial instability for the company. The success of personalized vaccines could lead to a wider wave of treatments for various cancer types.

    What is confirmed

    • A late-stage trial of a Moderna and Merck cancer vaccine showed promise in preventing melanoma from returning.
    • Moderna stock experienced a significant surge following the trial results.

    Still unconfirmed

    • Moderna stock jumped 177% in a single day.
    • Moderna stock soared 90%.

    What to watch next

    • Peer review of the late-stage trial data
    • FDA regulatory filing for the melanoma vaccine
    • Expansion of trials to other cancer types
    Sources used for this update (13)
    1. CNBC — Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
    2. The New York Times — Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
    3. The New York Times — From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day
    4. CNN — Moderna, Merck breakthrough could usher in wave of cancer vaccines
    5. The Economist — It now seems possible to vaccinate against cancer
    6. Yahoo Finance — Moderna's 177% Surge Powers a Broad Biotech Rally
    7. Bloomberg.com — Why Moderna’s Cancer Vaccine Is a Breakthrough for mRNA
    8. WSJ — How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
    9. RochesterFirst — Local Doctor weighs in on Merck & Moderna personalized mRNA cancer treatment
    10. WSJ — Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math
    11. The Washington Post — What it was like to go through a trial that could revolutionize cancer treatment
    12. National Geographic — Why Scientists Say This Personalized Cancer Vaccine Could Be a Game-Changer
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community